Prevalence and incidence of HPV genital infection in women

Sexually Transmitted Diseases

Volumn 36, Issue 11, 2009, Pages 696-703

  Velicer, Christine ^a   Zhu, Xingshu ^a   Vuocolo, Scott ^a   Liaw, Kai Li ^a   Saah, Alfred ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CHLAMYDIASIS; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRANCE; GENITAL TRACT INFECTION; GERMANY; GONORRHEA; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MARRIAGE; PERSISTENT VIRUS INFECTION; PHILIPPINES; PREDICTOR VARIABLE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SPAIN; THAILAND; UNITED STATES; VACCINATION; WART VIRUS;

ADULT; ANUS DISEASES; COLOMBIA; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHILIPPINES; PREVALENCE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEXUALLY TRANSMITTED DISEASES, VIRAL; THAILAND; TREATMENT OUTCOME; UNITED STATES; VACCINATION;

EID: 70350754599     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181ad25ff     Document Type: Article

References (30)

1. Daling JR, Madeleine MM, Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002; 84:263-270.
2. Ferenczy A, Mitao M, Nagai N, et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1985; 313:784-788.
3. Goffin F, Mayrand MH, Gauthier P, et al. High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neo-plasia. J Med Virol 2006; 78:814-819.
4. Melbye M, Frisch M. The role of human papillomaviruses in anogenital cancers. Semin Cancer Biol 1998; 8:307-313. (Pubitemid 28550388)
5. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5 Version 2 0 IARC Press Lyon, France; 2002. Available at: http://www-dep.iarc.fr/globocan/database.htm. Accessed October 15, 2008.
6. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virologic evidence of HPV infection. J Infect Dis 2007; 196:1438-1446.
7. Auvinen E, Niemi M, Malm C, et al. High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005; 37:873-876.
8. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191:182-192.
9. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173:1394-1398.
10. Manhart LE, Holmes KK, Koutsky LA, et al. Human papilloma-virus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 2006; 33:502-508.
11. Munoz N, Manalastas R, Pitisuttihum P, et al. Safety, Immuno-genicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age. Lancet. In press.
12. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10: 108-115.
13. Duttagupta C, Sengupta S, Roy M, et al. Are Muslim women less susceptible to oncogenic human papillomavirus infection? A study from rural eastern India Int J Gynecol Cancer 2004; 14: 293-303.
14. Laikangbam P, Sengupta S, Bhattacharya P, et al. A comparative profile of the prevalence and age distribution of human papillo-mavirus type 16/18 infections among three states of India with focus on northeast India. Int J Gynecol Cancer 2007; 17:107-117.
15. Li LK, Dai M, Clifford GM, et al. Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer 2006; 95:1593-1597. (Pubitemid 44863366)
16. Forslund O, Antonsson A, Edlund K, et al. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002; 66:535-541.
17. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neo-plasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1796-1807. (Pubitemid 40705385)
18. Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: Cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95:56-61.
19. Klug SJ, Hukelmann M, Hollwitz B, et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 2007; 79:616-625.
20. Peto J, Gilham C, Deacon J, et al. Cervical HPV infectionand neoplasia in a large population-based prospective study: The Manchester cohort. Br J Cancer 2004; 91:942-953.
21. Ylitalo N, Sørensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 2000; 355:2194-2198. (Pubitemid 30394326)
22. Newall A, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7:289-296.
23. Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papilloma-viruses in Finland in the 1980s and 1990s. Int J Cancer 2006; 119:2612-2619.
24. Chen CJ, Viscidi RP, Chuang CH, et al. Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: Implication for optimal age of human papillomavirus vaccination. J Clin Virol 2007; 38:126-130.
25. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16,-18,-31, and-45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003; 89: 1248-1254.
26. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 15:2077-2087.
27. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9:423-430.
28. Burchell AN, Winer RL, de Sanjose S, et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24(suppl 3):S52-S61.
29. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: A global perspective. Lancet 2006; 368:1706-1728.
30. Stevenson B, Wolfers J. Marriage and divorce: Changes and their driving forces. J Econ Perspect 2006; 21:27-52.